Drug Profile
AMG 221
Alternative Names: BVT 83370Latest Information Update: 26 Apr 2011
Price :
$50
*
At a glance
- Originator Biovitrum
- Developer Amgen
- Class Small molecules
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 21 Apr 2011 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (PO)
- 14 Jan 2010 Biovitrum has merged with Swedish Orphan forming Swedish Orphan Biovitrum
- 13 Feb 2006 Phase-I clinical trials in Type-2 diabetes mellitus in USA (unspecified route)